Investor Overview

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All clinical candidates were invented internally by Synta scientists using our compound library and discove... More >>

Date Title   01/16/12 Synta Announces Publication of Results Showing Ganetespib Synergizes with Taxanes in Multiple Non-small Cell Lung Cancer Models -Ganetespib and docetaxel display complementary cell cycle inhibition effects- -Combination of ganetespib with microtubule stabilizers (docetaxel and paclitaxel) or destabilizers (vincristine) results in synergistic anticancer activity- -Ganetespib and docetaxel combination currently being studied in a Phase 2b/3 clinical trial in non-small cell lung cancer- LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 16, 2012-- Synt...  01/12/12 Synta Pharmaceuticals and University of Toronto Researchers Elucidate Elesclomol Mechanism of Action Using Innovative Yeast-based Technology -Results support elesclomol results seen in human clinical trials- -Elesclomol clinical trials on-going in acute myeloid leukemia and ovarian cancer- LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 12, 2012-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) – A report published in the peer-reviewed journal PLoS ONE demonstrate how a novel yeast screening platform pioneered by researchers at the University of Toronto was used to elucidate the...  01/11/12 Synta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2012-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today the closing of its underwritten public offering of 7,000,000 shares of common stock at a public offering price of $4.40 per share. Net proceeds to Synta are approximately $28.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. Synta has granted the underwriters a thirty (30) ...